Cargando…
MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis
OBJECTIVE: Although the role of microRNA-17 (miR-17) has been identified as a tumour biomarker in various studies, its prognostic value in cancers remains unclear. Therefore, we performed a systematic review and meta-analysis to analyse and summarise the relationship between the miR-17 status and cl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988052/ https://www.ncbi.nlm.nih.gov/pubmed/29858404 http://dx.doi.org/10.1136/bmjopen-2017-018070 |
_version_ | 1783329222189645824 |
---|---|
author | Huang, Chengzhi Yu, Mengya Yao, Xueqing |
author_facet | Huang, Chengzhi Yu, Mengya Yao, Xueqing |
author_sort | Huang, Chengzhi |
collection | PubMed |
description | OBJECTIVE: Although the role of microRNA-17 (miR-17) has been identified as a tumour biomarker in various studies, its prognostic value in cancers remains unclear. Therefore, we performed a systematic review and meta-analysis to analyse and summarise the relationship between the miR-17 status and clinical outcome in a variety of human cancers. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Web of Science and Embase from the first year of records to 15 May 2017. OUTCOMES: The patients’ survival results were pooled, and pooled HRs with 95% CIs were calculated and used for measuring the strength of association between miR-17 and the prognosis of cancers, including hepatocellular carcinoma, lung cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma and colon cancer. Heterogeneity, publication bias and subgroup analysis were also conducted. RESULTS: A total of 1096 patients were included in this meta-analysis from 12 articles. The results indicated that the increased expression of miR-17 played an unfavourable role in overall survival in various human carcinomas with the HR of 1.342 taking into account the publication bias. In subgroup analysis, HR of ethnicity (Caucasian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and blood system cancer (HR=2.38), detection method (quantitative real-time PCR HR=1.40 and in situ hybridisation, HR=2.59) and detection sample (tissue HR=1.45 and serum HR=1.32) were significant with p<0.05. For the analysis of disease-free survival and recurrence-free survival, the increased expression of miR-17 was associated with unfavourable prognosis (HR=1.40). CONCLUSIONS: miR-17 may be a useful biomarker in predicting the clinical outcome of human cancers, but due to the limitations of the current studies, further verification of the role of miR-17 in human malignancies is urgently needed. PROSPERO REGISTRATION NUMBER: CRD42017065749 |
format | Online Article Text |
id | pubmed-5988052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-59880522018-06-07 MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis Huang, Chengzhi Yu, Mengya Yao, Xueqing BMJ Open Genetics and Genomics OBJECTIVE: Although the role of microRNA-17 (miR-17) has been identified as a tumour biomarker in various studies, its prognostic value in cancers remains unclear. Therefore, we performed a systematic review and meta-analysis to analyse and summarise the relationship between the miR-17 status and clinical outcome in a variety of human cancers. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Web of Science and Embase from the first year of records to 15 May 2017. OUTCOMES: The patients’ survival results were pooled, and pooled HRs with 95% CIs were calculated and used for measuring the strength of association between miR-17 and the prognosis of cancers, including hepatocellular carcinoma, lung cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma and colon cancer. Heterogeneity, publication bias and subgroup analysis were also conducted. RESULTS: A total of 1096 patients were included in this meta-analysis from 12 articles. The results indicated that the increased expression of miR-17 played an unfavourable role in overall survival in various human carcinomas with the HR of 1.342 taking into account the publication bias. In subgroup analysis, HR of ethnicity (Caucasian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and blood system cancer (HR=2.38), detection method (quantitative real-time PCR HR=1.40 and in situ hybridisation, HR=2.59) and detection sample (tissue HR=1.45 and serum HR=1.32) were significant with p<0.05. For the analysis of disease-free survival and recurrence-free survival, the increased expression of miR-17 was associated with unfavourable prognosis (HR=1.40). CONCLUSIONS: miR-17 may be a useful biomarker in predicting the clinical outcome of human cancers, but due to the limitations of the current studies, further verification of the role of miR-17 in human malignancies is urgently needed. PROSPERO REGISTRATION NUMBER: CRD42017065749 BMJ Publishing Group 2018-05-31 /pmc/articles/PMC5988052/ /pubmed/29858404 http://dx.doi.org/10.1136/bmjopen-2017-018070 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Genetics and Genomics Huang, Chengzhi Yu, Mengya Yao, Xueqing MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis |
title | MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis |
title_full | MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis |
title_fullStr | MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis |
title_full_unstemmed | MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis |
title_short | MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis |
title_sort | microrna-17 and the prognosis of human carcinomas: a systematic review and meta-analysis |
topic | Genetics and Genomics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988052/ https://www.ncbi.nlm.nih.gov/pubmed/29858404 http://dx.doi.org/10.1136/bmjopen-2017-018070 |
work_keys_str_mv | AT huangchengzhi microrna17andtheprognosisofhumancarcinomasasystematicreviewandmetaanalysis AT yumengya microrna17andtheprognosisofhumancarcinomasasystematicreviewandmetaanalysis AT yaoxueqing microrna17andtheprognosisofhumancarcinomasasystematicreviewandmetaanalysis |